Nihon Schering, Daiichi Radioisotope Laboratories to Collaborate in Sales of Radioimmunotherapy Agent Zevalin.
Tokyo, Japan, July 10, 2006 - (JCN) - Nihon Schering announced on June 4 that it signed a joint business contract with Daiichi Radioisotope Laboratories (DRL) regarding Zevalin, a radioimmunotherapy agent used in the treatment of non-Hodgkin's lymphoma.Zevalin (ibritumomab tiuxetan), which was initially approved in the US in 2002, is currently available in 37 countries worldwide.
Nippon Schering has applied a new drug application for Zevalin with the Ministry of Health, Labor and Welfare, as of June 23, and aims to obtain approval at the earliest date possible.
Upon receiving approval, the two companies will jointly promote and sell Zevalin in Japan. In particular, DRL will handle orders and distribution.
Copyright [c] 2006 Japan Corporate News Network. All rights reserved.
 Printer friendly
 Cite/link
 Email
 Feedback
| |
| Publication: | JCNN News Summaries |
|---|---|
| Date: | Jul 10, 2006 |
| Words: | 119 |
| Previous Article: | So-net M3, Senior Communication Introduce AskDoctors R50 Medical Consultation Service for Seniors. |
| Next Article: | Taiho Pharmaceutical, Sanofi-aventis Conclude Licensing Agreement for Oral Pyrimidine Fluoride-derived Anticancer Agent TS-1. |